Extrinsic pathway inhibitor--the key to feedback control of blood coagulation initiated by tissue thromboplastin.
Extrinsic pathway inhibitor (EPI) is a Kunitz type serine protease inhibitor. EPI is a potent inhibitor of the factor VIIa/thromboplastin (TP) complex in the presence of factor Xa and is also a direct inhibitor of factor Xa. The inhibitory mechanism is complex and is currently thought to involve, in a first step, the formation of a EPI-factor Xa complex, and, in a second step, the formation a quaternary EPI-factor Xa-factor VIIa-TP complex. In the blood vessels, EPI is confined to three different pools. A major pool of EPI is bound to the endothelial surface, and this fraction may be released by heparin. Plasma contains a second, but smaller pool of EPI (approximately 10-50% of the endothelial surface pool) at a concentration of 50-100 ng/ml. This pool consists mostly of EPI-lipoprotein complexes and only less than 10% is carrier-free EPI. A third pool of EPI is confined to platelets (less than 10% of the plasma pool). The biological role of these pools has not yet been clarified, but some evidence suggest that the carrier-free EPI is biologically most active. In patients, disseminated intravascular coagulation may continue despite normal or even elevated EPI levels. However, evidence has now been provided to indicate that EPI can inhibit factor VIIa/TP complexes formed in vivo to prevent the effect of limited amounts of TP. Taken together, the present knowledge of EPI indicates that EPI functions as a key inhibitor to feedback control of blood coagulation initiated by TP.
Sandset
P M
PM
Department of Medicine, Aker University Hospital, Oslo, Norway.
Abildgaard
U
U
D001777:Blood Coagulation / Q000502:physiology*; D001792:Blood Platelets / Q000378:metabolism; D004211:Disseminated Intravascular Coagulation / Q000097:blood; D004730:Endothelium, Vascular / Q000378:metabolism; D005167:Factor VII / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000502:physiology; D015942:Factor VIIa / Q000037:antagonists & inhibitors*; D065427:Factor Xa Inhibitors; D005246:Feedback; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism / Q000502:physiology*; D008107:Liver Diseases / Q000097:blood; D009369:Neoplasms / Q000097:blood; D011994:Recombinant Proteins / Q000494:pharmacology; D012016:Reference Values; D018805:Sepsis / Q000097:blood; D013925:Thromboplastin / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000502:physiology
D065427:Factor Xa Inhibitors; D008074:Lipoproteins; D011994:Recombinant Proteins; C051928:lipoprotein-associated coagulation inhibitor; D005167:Factor VII; D006493:Heparin; D013925:Thromboplastin; D015942:Factor VIIa